Delia Deschaine Quoted in “Strategic Perspectives: Notable 2020 Developments for Life Sciences”Wolters Kluwer Health Law Daily December 7, 2020
Delia A. Deschaine, Member of the Firm in the Health Care & Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Wolters Kluwer Health Law Daily, in “Strategic Perspectives: Notable 2020 Developments for Life Sciences,” by Anthony H. Nguyen.
Following is an excerpt (see below to download the full version in PDF format):
The FDA continues with its mission of regulating food, drugs, and medical devices during an unprecedented year in coping with the myriad challenges presented by the coronavirus 2019 disease (COVID-19). In navigating the complexities of addressing COVID-19, both from a practical and political standpoint, the FDA continued to address drug and food regulation and modernization. Further, the results of the 2020 national election demonstrated that cannabis and cannabinoid products are gaining acceptance among the states, increasing pressure on the federal government to reconsider its stance. This Strategic Perspective reviews some of the top life sciences developments from 2020 and highlights their implications in 2021.
COVID-19 Treatments and Vaccines – Public Confidence …
Likewise, Delia A. Deschaine, Member at Epstein Becker Green, in commentary to Wolters Kluwer, stressed that the FDA’s transparency throughout the vaccine review and approval process is key to instilling public confidence in any potential vaccine. Deschaine noted that transparency can also help by giving “healthcare providers, who prescribe the vaccine, to have confidence in the vaccine’s safety and efficacy, and communicate that confidence to their patients.”